Gary V. Walker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gary V. Walker has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
Stephen R. Grant
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
3 shared publicationsAnna O. Likhacheva
Department of Radiation Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona
2 shared publicationsBenjamin D. Smith
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
2 shared publications- Benjamin D. Smith
MD Anderson Cancer Center, Houston, TX
2 shared publications Pamela Allen
The University of Texas MD Anderson Cancer Center, Houston, TX
2 shared publicationsRachit Kumar
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
2 shared publications
Latest Publications
- Top Cited Papers
- 16 May 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44  (29) , 2787-2799
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial
PURPOSE: We tested the hypothesis that adding metastasis-directed therapy (MDT) to standard-of-care (SOC) systemic therapy improves progression-free survival (PFS) among patients with oligometastatic disease. METHODS: EXTEND was a multicenter randomized phase II trial. Patients with 1-5 metastases were randomly assigned to MDT + SOC versus SOC in one of the six baskets (breast, pancreas, kidney, two prostate baskets, and an other basket) with basket-specific stratification and powering. PFS, the primary end point, was prespecified in the per-protocol set within each basket, across all baskets, and across all baskets excluding the prostate baskets. Exploratory end points included circulating tumor DNA (ctDNA) and immune profiling. RESULTS: From 2018 through 2023, 521 patients were screened, 350 were randomly assigned, and 334 were analyzed per protocol (MDT + SOC, n = 166; SOC, n = 168). Radiotherapy was used as MDT for 98% of metastases (370/379). Overall, after a median follow-up of 53 months, PFS was improved with MDT + SOC (hazard ratio [HR], 0.54 [95% CI, 0.41 to 0.72], P < .001). Similarly, PFS was improved when excluding the prostate baskets (HR, 0.60 [95% CI, 0.40 to 0.89]). Within each basket, PFS superiority was identified for the pancreas, prostate, and other baskets, whereas the breast and kidney baskets were inconclusive. At enrollment, detectable ctDNA correlated with shorter PFS and survival; by contrast, ctDNA clearance 3 months postenrollment correlated with improved survival. MDT + SOC-induced systemic immune activation was most pronounced among baskets demonstrating PFS superiority. CONCLUSION: The phase II EXTEND trial supports the addition of MDT to SOC for oligometastatic disease. Histology-specific efficacy signals were identified for phase III testing. Translational insights suggest the potential for optimizing the definition of oligometastasis using ctDNA and point to systemic immune responses as a possible mechanism of benefit from MDT.
- 16 May 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44  (29) , 2787-2799
Top Cited PapersAddition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial
PURPOSE: We tested the hypothesis that adding metastasis-directed therapy (MDT) to standard-of-care (SOC) systemic therapy improves progression-free survival (PFS) among patients with oligometastatic disease. METHODS: EXTEND was a multicenter randomized phase II trial. Patients with 1-5 metastases were randomly assigned to MDT + SOC versus SOC in one of the six baskets (breast, pancreas, kidney, two prostate baskets, and an other basket) with basket-specific stratification and powering. PFS, the primary end point, was prespecified in the per-protocol set within each basket, across all baskets, and across all baskets excluding the prostate baskets. Exploratory end points included circulating tumor DNA (ctDNA) and immune profiling. RESULTS: From 2018 through 2023, 521 patients were screened, 350 were randomly assigned, and 334 were analyzed per protocol (MDT + SOC, n = 166; SOC, n = 168). Radiotherapy was used as MDT for 98% of metastases (370/379). Overall, after a median follow-up of 53 months, PFS was improved with MDT + SOC (hazard ratio [HR], 0.54 [95% CI, 0.41 to 0.72], P < .001). Similarly, PFS was improved when excluding the prostate baskets (HR, 0.60 [95% CI, 0.40 to 0.89]). Within each basket, PFS superiority was identified for the pancreas, prostate, and other baskets, whereas the breast and kidney baskets were inconclusive. At enrollment, detectable ctDNA correlated with shorter PFS and survival; by contrast, ctDNA clearance 3 months postenrollment correlated with improved survival. MDT + SOC-induced systemic immune activation was most pronounced among baskets demonstrating PFS superiority. CONCLUSION: The phase II EXTEND trial supports the addition of MDT to SOC for oligometastatic disease. Histology-specific efficacy signals were identified for phase III testing. Translational insights suggest the potential for optimizing the definition of oligometastasis using ctDNA and point to systemic immune responses as a possible mechanism of benefit from MDT.
- 1 November 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18  (11) , e1725-e1731
Factors Associated With Image-Guided Radiation Therapy Image Rejection in a Multisite Institution
Nonclinical factors and cognitive biases have been shown to significantly affect clinical decision making. In this study, we aimed to identify clinical and environmental factors that might influence the decision to approve or reject image-guided radiation therapy (IGRT) images in a large multisite institution. We identified all IGRT image approval and rejection decisions recorded within an electronic imaging system from July 1, 2016, to June 30, 2018. For each decision, we tabulated the following parameters: the attending physician of the patient, the physician reviewing the image, total images reviewed by the physician that day, time of day, day of week, treatment site, and imaging modality (kilovoltage or cone beam computed tomography [CBCT]). We created a binary multivariable logistic regression model to identify factors associated with IGRT image rejection. Overall, of 51,797 total image records evaluated, 881 (1.70%) were rejected and 50,916 (98.30%) were approved. Univariable analysis revealed that images reviewed by physicians with high rejection rates (odds ratio [OR], 3.16; P < .001) and by physicians reviewing fewer IGRT images (OR, 0.99; P = .024), images from various anatomic sites (particularly skin, breast, and head and neck), and CBCT imaging compared with kilovoltage imaging (OR, 1.49; P < .001) were associated with the increased rate of rejection. On multivariable analysis, images reviewed by physicians with high rejection rates (OR, 3.28; P < .001), images from specific anatomic sites including breast (P < .001), and CBCT imaging (P < .001) persisted as independent predictors of image rejection. These data provide important insight into the clinical, cognitive, and environmental factors that might influence the routine clinical decision of IGRT image approval. Recognition of these factors may not only improve the quality of individual decisions but also identify opportunities for systems-based quality improvement in IGRT.
- 1 November 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18  (11) , e1725-e1731
Factors Associated With Image-Guided Radiation Therapy Image Rejection in a Multisite Institution
Nonclinical factors and cognitive biases have been shown to significantly affect clinical decision making. In this study, we aimed to identify clinical and environmental factors that might influence the decision to approve or reject image-guided radiation therapy (IGRT) images in a large multisite institution. We identified all IGRT image approval and rejection decisions recorded within an electronic imaging system from July 1, 2016, to June 30, 2018. For each decision, we tabulated the following parameters: the attending physician of the patient, the physician reviewing the image, total images reviewed by the physician that day, time of day, day of week, treatment site, and imaging modality (kilovoltage or cone beam computed tomography [CBCT]). We created a binary multivariable logistic regression model to identify factors associated with IGRT image rejection. Overall, of 51,797 total image records evaluated, 881 (1.70%) were rejected and 50,916 (98.30%) were approved. Univariable analysis revealed that images reviewed by physicians with high rejection rates (odds ratio [OR], 3.16; P < .001) and by physicians reviewing fewer IGRT images (OR, 0.99; P = .024), images from various anatomic sites (particularly skin, breast, and head and neck), and CBCT imaging compared with kilovoltage imaging (OR, 1.49; P < .001) were associated with the increased rate of rejection. On multivariable analysis, images reviewed by physicians with high rejection rates (OR, 3.28; P < .001), images from specific anatomic sites including breast (P < .001), and CBCT imaging (P < .001) persisted as independent predictors of image rejection. These data provide important insight into the clinical, cognitive, and environmental factors that might influence the routine clinical decision of IGRT image approval. Recognition of these factors may not only improve the quality of individual decisions but also identify opportunities for systems-based quality improvement in IGRT.
- 1 January 2022
- Published by Elsevier in Brachytherapy
- Vol. 21  (1) , 6-11
PSA: Declining utilization of prostate brachytherapy
- 1 January 2022
- Published by Elsevier in Brachytherapy
- Vol. 21  (1) , 6-11
PSA: Declining utilization of prostate brachytherapy
- Open Access
- 28 October 2019
- Published by Springer Nature in Cureus
- Vol. 11  (10) , e6010
Development of a Natural Language Processing Tool to Extract Radiation Treatment Sites
Currently, radiation oncology-specific electronic medical records (EMRs) allow providers to input the radiation treatment site using free text. The purpose of this study is to develop a natural language processing (NLP) tool to extract encoded data from radiation treatment sites in an EMR. Treatment sites were extracted from all patients who completed treatment in our department from April 1, 2011, to April 30, 2013. A system was designed to extract the Unified Medical Language System (UMLS) concept codes using a sample of 11,018 unique site names from 31118 radiation therapy (RT) sites. Among those, 5500 unique site name strings that constitute approximately half of the sample were spared as a test set to evaluate the final system. A dictionary and calculated n-gram statistics using UMLS concepts from related semantic types were combined with manually encoded data. There was an average of 2.2 sites per patient. Prior to extraction, the 20 most common unique treatment sites were used 4215 times (38.3%). The most common treatment site was whole brain RT, which was entered using 27 distinct terms for a total of 1063 times. The customized NLP solution displayed great gains as compared to other systems, with a recall of 0.99 and a precision of 0.99. A customized NLP tool was extracting encoded data from radiation treatment sites in an EMR with great accuracy. This can be integrated into a repository of demographic, genomic, treatment, and outcome data to advance personalized oncologic care.
- 28 October 2019
- Published by Springer Nature in Cureus
- Vol. 11  (10) , e6010
Open AccessDevelopment of a Natural Language Processing Tool to Extract Radiation Treatment Sites
Currently, radiation oncology-specific electronic medical records (EMRs) allow providers to input the radiation treatment site using free text. The purpose of this study is to develop a natural language processing (NLP) tool to extract encoded data from radiation treatment sites in an EMR. Treatment sites were extracted from all patients who completed treatment in our department from April 1, 2011, to April 30, 2013. A system was designed to extract the Unified Medical Language System (UMLS) concept codes using a sample of 11,018 unique site names from 31118 radiation therapy (RT) sites. Among those, 5500 unique site name strings that constitute approximately half of the sample were spared as a test set to evaluate the final system. A dictionary and calculated n-gram statistics using UMLS concepts from related semantic types were combined with manually encoded data. There was an average of 2.2 sites per patient. Prior to extraction, the 20 most common unique treatment sites were used 4215 times (38.3%). The most common treatment site was whole brain RT, which was entered using 27 distinct terms for a total of 1063 times. The customized NLP solution displayed great gains as compared to other systems, with a recall of 0.99 and a precision of 0.99. A customized NLP tool was extracting encoded data from radiation treatment sites in an EMR with great accuracy. This can be integrated into a repository of demographic, genomic, treatment, and outcome data to advance personalized oncologic care.
- 1 September 2018
- Published by Elsevier in Practical Radiation Oncology
- Vol. 8  (5) , e329-e336
Provider variability in intensity modulated radiation therapy utilization among Medicare beneficiaries in the United States
- 1 September 2018
- Published by Elsevier in Practical Radiation Oncology
- Vol. 8  (5) , e329-e336
Provider variability in intensity modulated radiation therapy utilization among Medicare beneficiaries in the United States
- 1 September 2018
- Published by Elsevier in Practical Radiation Oncology
- Vol. 8  (5) , e251-e254
The great esophageal escape: A case of extreme esophageal interfraction motion during neoadjuvant chemoradiation therapy
- 1 September 2018
- Published by Elsevier in Practical Radiation Oncology
- Vol. 8  (5) , e251-e254
The great esophageal escape: A case of extreme esophageal interfraction motion during neoadjuvant chemoradiation therapy
- 1 August 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 14  (8) , e513-e516
Palliation or Prolongation? The Impact of a Peer-Review Intervention on Shortening Radiotherapy Schedules for Bone Metastases
Purpose: Shorter fractionation radiation regimens for palliation of bone metastases result in lower financial and social costs for patients and their caregivers and have similar efficacy as longer fractionation schedules, although practice patterns in the United States show poor adoption. We investigated whether prospective peer review can increase use of shorter fractionation schedules. Methods: In June 2016, our practice mandated peer review of total dose and fractionation for all patients receiving palliative treatment during our weekly chart rounds. We used descriptive statistics and Fisher’s exact test to compare lengths of treatment of uncomplicated bone metastases before and after implementation of the peer review process. Results: Between July 2015 and December 2016, a total of 242 palliative treatment courses were delivered, including 105 courses before the peer review intervention and 137 after the intervention. We observed greater adoption of shorter fractionation regimens after the intervention. The use of 8 Gy in one fraction increased from 2.8% to 13.9% of cases postadoption. Likewise, the use of 20 Gy in five fractions increased from 25.7% to 32.8%. The use of 30 Gy in 10 fractions decreased from 55.2% to 47.4% ( P = .002), and the use of ≥ 11 fractions decreased from 16.2% before the intervention to 5.8% after ( P = .006). Conclusion: Prospective peer review of palliative regimens for bone metastases can lead to greater adoption of shorter palliative fractionation schedules in daily practice, in accordance with national guidelines. This simple intervention may therefore benefit patients and their caregivers as well as provide value to the health care system.
- 1 August 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 14  (8) , e513-e516
Palliation or Prolongation? The Impact of a Peer-Review Intervention on Shortening Radiotherapy Schedules for Bone Metastases
Purpose: Shorter fractionation radiation regimens for palliation of bone metastases result in lower financial and social costs for patients and their caregivers and have similar efficacy as longer fractionation schedules, although practice patterns in the United States show poor adoption. We investigated whether prospective peer review can increase use of shorter fractionation schedules. Methods: In June 2016, our practice mandated peer review of total dose and fractionation for all patients receiving palliative treatment during our weekly chart rounds. We used descriptive statistics and Fisher’s exact test to compare lengths of treatment of uncomplicated bone metastases before and after implementation of the peer review process. Results: Between July 2015 and December 2016, a total of 242 palliative treatment courses were delivered, including 105 courses before the peer review intervention and 137 after the intervention. We observed greater adoption of shorter fractionation regimens after the intervention. The use of 8 Gy in one fraction increased from 2.8% to 13.9% of cases postadoption. Likewise, the use of 20 Gy in five fractions increased from 25.7% to 32.8%. The use of 30 Gy in 10 fractions decreased from 55.2% to 47.4% ( P = .002), and the use of ≥ 11 fractions decreased from 16.2% before the intervention to 5.8% after ( P = .006). Conclusion: Prospective peer review of palliative regimens for bone metastases can lead to greater adoption of shorter palliative fractionation schedules in daily practice, in accordance with national guidelines. This simple intervention may therefore benefit patients and their caregivers as well as provide value to the health care system.
- 31 December 2017
- Published by Springer Nature
- p. 129-143
Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
- 31 December 2017
- Published by Springer Nature
- p. 129-143
Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99  (2) , 302-303
Reducing Bias in Oncology Research: The End of the Radiation Variable in the Surveillance, Epidemiology, and End Results (SEER) Program
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99  (2) , 302-303
Reducing Bias in Oncology Research: The End of the Radiation Variable in the Surveillance, Epidemiology, and End Results (SEER) Program
- 1 December 2016
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 13  (12) , 1514-1516.e6
Development of a Comprehensive Clinical Radiation Oncology Resident Didactic Curriculum
- 1 December 2016
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 13  (12) , 1514-1516.e6
Development of a Comprehensive Clinical Radiation Oncology Resident Didactic Curriculum